Results 261 to 270 of about 532,092 (302)
Some of the next articles are maybe not open access.

Anti‐vascular endothelial growth factor for myopic choroidal neovascularization

Clinical & Experimental Ophthalmology, 2012
AbstractMyopic choroidal neovascularization (CNV) is a vision‐threatening complication in the eyes with pathological myopia, which is particularly prevalent among young and middle‐aged Asians globally. To date, the verteporfin in photodynamic therapy study is the only randomized‐controlled study in treatment of subfoveal myopic CNV.
Danny S, Ng   +2 more
openaire   +2 more sources

Anti-Vascular Endothelial Growth Factor Monoclonal Antibodies

2009
As tumors grow and metastasize, they require the formation of new blood vessels or angiogenesis. This process is regulated by a complex balance of pro- and antiangiogenic factors. One of these factors, vascular endothelial growth factor (VEGF), has been extensively studied and found to be an important stimulatory signal that drives angiogenesis.
Ernest S. Han, Bradley J. Monk
openaire   +1 more source

Anti-vascular endothelial growth factor agents for diabetic maculopathy

British Journal of Ophthalmology, 2009
The management of diabetic macular oedema is changing. The therapeutic armamentarium for diabetic macular oedema (DMO) includes a new group of drugs that inhibit vascular endothelial growth factor (VEGF). These anti-VEGF agents are already being used widely in DMO in clinical practice despite that several phase III trials on these drugs are still ...
A, Salam, J, DaCosta, S, Sivaprasad
openaire   +2 more sources

Medicare Spending on Anti–Vascular Endothelial Growth Factor Medications

Ophthalmology Retina, 2018
To analyze Medicare Part B spending on anti-vascular endothelial growth factor (VEGF) medications.Observational cohort study using Medicare Part B claims data released by the Centers for Medicare and Medicaid Services.Medicare Part B beneficiaries and their providers.Data from 2011 through 2015 were used to analyze intravitreal injection claims for ...
openaire   +2 more sources

Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Pachychoroid Neovasculopathy

Journal of Ocular Pharmacology and Therapeutics, 2019
To compare the effectiveness of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment for pachychoroid neovasculopathy and neovascular age-related macular degeneration (AMD).Twenty-two eyes with pachychoroid neovasculopathy and 183 eyes with neovascular AMD were retrospectively included for analysis.
Han Joo, Cho   +5 more
openaire   +2 more sources

Anti-vascular endothelial growth factor and retinopathy of prematurity

British Journal of Ophthalmology, 2008
Retinopathy of prematurity1 (ROP) has been at the nexus of a progressive understanding of neovascularisation, in large part because of the mouse model of oxygen-induced retinopathy (OIR) developed by Lois Smith.2 This model has been very instructive, because it has crystallised the hypothesis that ROP in general is caused by a two-step or two-phase ...
openaire   +2 more sources

Ocular Hypertension Following Intravitreal Anti-vascular Endothelial Growth Factor Agents

Drugs & Aging, 2012
Age-related macular degeneration (AMD) is the leading cause of severe vision loss in adults over the age of 65 years. The advent of anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections has revolutionized the management of exudative AMD.
Ravi S J, Singh, Judy E, Kim
openaire   +2 more sources

Anti-Vascular Endothelial Growth Factor Treatment for Retinal Vein Occlusions

Ophthalmologica, 2012
Retinal vein occlusion (RVO) encompasses two conditions: central RVO, in which the major outflow vessel of the retina is obstructed, and branch RVO, in which a proximal branch of the central retinal vein is obstructed. In both conditions, there is increased intraluminal and interstitial pressure throughout the retina drained by the obstructed vessels ...
openaire   +2 more sources

Home - About - Disclaimer - Privacy